文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

免疫功能受损成人肺孢子菌肺炎的临床病程、治疗与结局:17年回顾性分析

Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years.
PubMed 文献 · Crit Care · 2018-11-19
一句话结论免疫功能受损成人PcP院内死亡率25.4%,需ICU者升至58%;初始LDH可作分层工具,低于推荐剂量TMP-SMX与更高死亡风险相关。

该单中心回顾性分析纳入17年间240例经微生物学确诊的肺孢子菌肺炎(PcP)免疫功能受损成人,其中52%为HIV阳性,其余为实体器官移植受者(16.3%)、恶性肿瘤(15.8%)或自身免疫病(11.7%)。95%的患者未接受化学预防。总体院内死亡率为25.4%,需要ICU入住者升至58%。多变量回归显示LDH为院内死亡预测因子(校正OR 1.17,95%CI 1.09-1.27,p<0.0001),LDH四分位组死亡率从8%升至49%,临界值495 U/L预测死亡的敏感度和特异度均为70%。40%的患者接受低于推荐剂量的甲氧苄啶-磺胺甲噁唑,其死亡风险更高(HR 1.80,95%CI 1.10-3.44,p=0.02)。

要点

  • PcP患者总体院内死亡率25.4%,需要ICU入住者死亡率升至58%。
  • 多变量回归显示LDH为院内死亡预测因子(校正OR 1.17,95%CI 1.09-1.27,p<0.0001)。
  • LDH四分位组死亡率从8%升至49%,临界值495 U/L预测死亡的敏感度和特异度均为70%。
  • 40%的患者接受低于推荐剂量的甲氧苄啶-磺胺甲噁唑,这些患者死亡风险更高(HR 1.80,95%CI 1.10-3.44,p=0.02)。
  • 95%的PcP患者未接受化学预防;约半数PcP患者HIV阳性(52%)。

适用人群与场景

  • 免疫功能受损成人PcP患者,包括HIV阳性(52%)、实体器官移植受者(16.3%)、恶性肿瘤(15.8%)和自身免疫病患者(11.7%)。
  • 单中心三级医疗机构17年间经微生物学确诊的PcP患者。

诊断标准与关键阈值

  • PcP诊断需典型临床特征和肺孢子菌(Pneumocystis jirovecii)微生物学确认。
  • LDH临界值495 U/L预测院内死亡,敏感度和特异度均为70%。

处置流程与药物剂量

  • 40%的患者接受低于推荐剂量的甲氧苄啶-磺胺甲噁唑治疗,这些患者死亡风险更高(HR 1.80,95%CI 1.10-3.44,p=0.02)。

红旗征与不能漏的情况

  • 需要ICU入住的PcP患者院内死亡率升至58%。

研究设计与关键结果

  • 单中心回顾性分析,17年间共52,364份标本来自7,504例患者送检微生物学评估(其中3,653例临床怀疑肺孢子菌肺炎),240例确诊PcP。
  • 总体院内死亡率为25.4%,需要ICU入住者死亡率升至58%。
  • 多变量回归识别LDH为院内死亡预测因子(校正OR 1.17,95%CI 1.09-1.27,p<0.0001);LDH四分位组死亡率从8%升至49%,临界值495 U/L预测死亡的敏感度和特异度均为70%。
  • 40%的患者接受低于推荐剂量的甲氧苄啶-磺胺甲噁唑,其死亡风险更高(HR 1.80,95%CI 1.10-3.44,p=0.02)。
  • 95%的PcP患者未接受化学预防。

证据类型、等级与局限

  • 单中心回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在免疫功能受损成人中,初始LDH值可能作为分层工具,用于识别HIV阳性和HIV阴性PcP患者中死亡高风险者(作者结论)。
  • 接受低于推荐剂量甲氧苄啶-磺胺甲噁唑的患者死亡风险更高(HR 1.80,95%CI 1.10-3.44,p=0.02)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Despite modern intensive care with standardized strategies against acute respiratory distress syndrome (ARDS), Pneumocystis pneumonia (PcP) remains a life-threatening disease with a high mortality rate. Here, we analyzed a large mixed cohort of immunocompromised patients with PcP, with regard to clinical course and treatment, and aimed at identifying predictors of outcome.

METHODS: This was a single-center retrospective analysis in a tertiary care institution across 17 years. Diagnosis of PcP required typical clinical features and microbiological confirmation of Pneumocystis jirovecii. Epidemiological, clinical, laboratory and outcome data were collected from patient records.

RESULTS: A total of 52,364 specimens from 7504 patients were sent for microbiological assessment (3653 with clinical suspicion of Pneumocystis pneumonia). PcP was confirmed in 240 patients, about half of them HIV positive (52%). The remaining subjects were either solid organ transplant recipients (16.3%) or suffered from malignancy (15.8%) or autoimmune diseases (11.7%). Of note, 95% of patients with PcP were not receiving chemoprophylaxis. Overall in-hospital mortality was 25.4%, increasing to 58% if ICU admission was required. Multivariable regression identified lactate dehydrogenase (LDH) as predictor of in-hospital mortality (adjusted OR 1.17 (95% CI 1.09-1.27), p < 0.0001). Mortality in LDH quartiles increased from 8% to 49%, and a cutoff value of 495 U/L predicted mortality with sensitivity and specificity of 70%. With regard to treatment, 40% of patients received trimethoprim-sulfamethoxazole at doses that were lower than recommended, and these patients had a higher mortality risk (HR 1.80 (95% CI 1.10-3.44), p = 0.02).

CONCLUSIONS: PcP remains a life-threatening disease among immunocompromised patients. About half of patients with PcP do not have HIV infection. Initial LDH values might serve as a stratifying tool to identify those patients at high risk of death among patients with HIV and without HIV infection.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Schmidt JJ, Lueck C, Ziesing S, et al. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Crit Care. 2018. PMID: 30454031. doi:10.1186/s13054-018-2221-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。